Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

ARNA 4.30 -0.09 (-2.05%)
price chart
Biotech Stocks with Optimistic Trend - Arena Pharmaceuticals, Inc. (NASDAQ ...
Mr. Hoffman is expected to remain in his current role at Arena until July 10, 2015. “Robert has been a valuable member of our management team and, on behalf of myself and the company, I thank him for his years of leadership and service to Arena,” said ...
Company Shares of Arena Pharmaceuticals, Inc. Drops by -0.68%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has dropped 0.68% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 11.85% in the last 4 weeks.
Stock Insights on Arena Pharmaceuticals Inc (NASDAQ:ARNA)
[PRNewswire] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) announced that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue ...
3 Biotech Stocks Are Getting Crushed – Arena Pharmaceuticals, Inc. (NASDAQ ...  Wall Street Observer
Stocks Plunging - Arena Pharmaceuticals (ARNA), Paragon Offshore (PGN ...  Investor Wired
Arena Pharmaceuticals, Inc. Short Interest Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has seen a shortfall of 260,771 shares or 0.8% in the short interest. The remaining shorts are 12.8% of the total floated shares.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stock Rating Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has been issued a 2.5 rating by the sell-side brokerage firms covering the stock.
Investor Insights on Arena Pharmaceuticals Inc (NASDAQ:ARNA)
The time has come for a monthly report on television advertising for Belviq from Arena Pharmaceuticals (NASDAQ:ARNA).
Large Outflow of Money Witnessed in Arena Pharmaceuticals, Inc.  News Watch International
Arena Pharmaceuticals, Inc. Analyst Rating Update  OTC Outlook
Zacks Short Term Rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a hold, according to the latest average broker rating of 2.5. The number of analysts in this rating is 6. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation ...
Pre- Market News Review: Ctrip.com International, (NASDAQ:CTRP), Arena ...
Arena Pharmaceuticals, Inc. (ARNA) declared that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue another opportunity in the biotechnology industry.
Can Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise Analysts this Quarter?
In the most recent quarter, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported an earnings surprise of 28.57% when the firm last announced their results for the period ending on 2015-03-31.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Price Target Update  OTC Outlook
Arena Pharmaceuticals, Inc. Price Target Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The mean estimate for the short term price target for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stands at $5.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $8 ...